美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

羅文

10.93

0.0000

成交量：- -

成交額：- -

市值：13.91億

市盈率：-3.99

高：10.93

開：10.93

低：10.93

收：10.93

52周最高：20.87

52周最低：7.77

股本：1.27億

流通股本：1.06億

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-2.7400

每股收益(LYR):-2.7376

淨資產收益率：--

總資產收益率：--

市淨率：0.28

市盈率(LYR):-3.99

資料載入中...

總覽公司新聞資訊公告

中國移動內蒙古公司通遼RDC東部集中庫榮膺國內倉儲行業最高榮譽

和鉑醫藥與藍納成宣佈達成長期戰略合作，攜手推進新一代RDC藥物開發

核藥進展如潮湧！遠大醫藥(00512)創新RDC藥物TLX591-CDx國內III期達到主要臨牀終點，診療一體化佈局蓄勢待發

市場監管總局局長羅文：市場監管部門將加強反壟斷和反不正當競爭執法

羅文在京調研國慶中秋節前食品安全、特種設備安全及重要民生商品穩價保質等工作

国家市场监督管...

觀察｜上海浦東：營商服務「最後一公里」，如何成就「最優一公里」？

據國藥控股消息近日經上海市藥品監督管理局批准國藥控股所屬分銷中心獲得《放射性藥品經營許可證》國藥控股正式進入放射性核素偶

【券商聚焦】中信證券：預計未來中國前列腺癌RDC診療市場將超100億元

中信證券研報表示創新核藥RDC有望解決目前前列腺癌診療過程中檢測負擔大、療效有限等未被滿足臨牀需求改變前列腺癌診療範式實

思路迪醫藥股份(01244.HK)：新型放射性核素偶聯藥物3D1015首次人體給藥成功

思路迪醫藥股份：新型放射性核素偶聯藥物3D1015首次人體給藥成功

格隆汇资讯

中信證券研報表示創新核藥RDC有望解決目前前列腺癌診療過程中檢測負擔大、療效有限等未被滿足臨牀需求改變前列腺癌診療範式實

市場監管總局羅文：「十四五」期間審結平台經濟自然壟斷等重點領域的經營者集中案件3400件

從易甘泰到RDC矩陣：核藥龍頭遠大醫藥蓄勢待發

中期業績穩健增長遠大醫藥股價升逾4% 核藥營收翻倍穩居領軍企業地位

智通财经网

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/RDC/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"RDC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RDC\",,,,,undefined,":{"symbol":"RDC","market":"US","secType":"STK","nameCN":"羅文","latestPrice":10.93,"timestamp":1575925200000,"preClose":10.93,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":105959169,"shares":127294643,"eps":-2.74,"marketStatus":"退市","change":0,"latestTime":"02-12 12:48:40 EST","open":10.93,"high":10.93,"low":10.93,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.74,"tradingStatus":0,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1770930000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":-73684800000,"exchange":"NYSE","adjPreClose":10.93,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RDC\",,,,,undefined,":{"symbol":"RDC","floatShares":105959169,"roa":"--","roe":"--","lyrEps":-2.737588,"shares":127294643,"dividePrice":0,"high":10.93,"amplitude":0,"preClose":10.93,"low":10.93,"week52Low":7.77,"pbRate":"0.28","week52High":20.87,"institutionHeld":0.8565,"latestPrice":10.93,"eps":-2.74,"divideRate":0,"volume":0,"delay":0,"ttmEps":-2.74,"open":10.93},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RDC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-02-27","symbol":"RDC","fiscalQuarterEnding":"2018/12","expectedEps":-1.07,"name":null,"time":"盤前","type":"earning","dateTimestamp":1551243600000,"reportTimeType":"pre","actualEps":-1.11},{"market":"US","date":"2018-10-31","symbol":"RDC","fiscalQuarterEnding":"2018/09","expectedEps":-1.15,"name":null,"time":"盤前","type":"earning","dateTimestamp":1540958400000,"reportTimeType":"pre","actualEps":-1.13},{"market":"US","date":"2018-08-01","symbol":"RDC","fiscalQuarterEnding":"2018/06","expectedEps":-0.93,"name":null,"time":"盤前","type":"earning","dateTimestamp":1533096000000,"reportTimeType":"pre","actualEps":-0.6},{"market":"US","date":"2018-05-01","symbol":"RDC","fiscalQuarterEnding":"2018/03","expectedEps":-0.86,"name":null,"time":"盤前","type":"earning","dateTimestamp":1525147200000,"reportTimeType":"pre","actualEps":-0.89},{"market":"US","date":"2018-02-28","symbol":"RDC","fiscalQuarterEnding":"2017/12","expectedEps":-0.26,"name":null,"time":"盤前","type":"earning","dateTimestamp":1519794000000,"reportTimeType":"pre","actualEps":-0.31}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RDC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RDC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RDC\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2601351442","title":"中國移動內蒙古公司通遼RDC東部集中庫榮膺國內倉儲行業最高榮譽","url":"https://stock-news.laohu8.com/highlight/detail?id=2601351442","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601351442?lang=zh_tw&edition=fundamental","pubTime":"2026-01-08 16:34","pubTimestamp":1767861240,"startTime":"0","endTime":"0","summary":"　　此次获评“五星级仓库”，不仅是对内蒙古移动通辽RDC东部集中库基础设施与技术能力的认可，更是对企业日常运营管理体系与服务品质的充分肯定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-01-08/doc-inhfqtyt1318665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0871576103.HKD","BK1610","LU0880133367.SGD","LU1152091754.HKD","LU1064131003.USD","LU2148510915.USD","RDC","LU0164880469.USD","BK1521","LU1152091168.USD","LU1226287875.USD","LU0039217434.USD","LU0516422440.USD","600941","SG9999002463.SGD","LU0516423091.SGD","80883","SGXZ81163826.USD","LU0516422366.SGD","CHL","LU0164865239.USD","LU0516422952.EUR","LU1481107354.HKD","LU1960683339.HKD","LU1497733631.SGD","LU1497734951.SGD","SGXZ49509284.SGD","BK1536","LU1328615791.USD","LU1993786604.SGD","BK1152","LU1807302812.USD","LU1497733557.USD","LU1064130708.USD","LU1226287792.SGD","BK1506","LU1226287529.USD","LU0149721374.USD","LU0531971595.HKD","HK0000500386.USD","LU1226288253.USD","LU1522347837.USD","00941","BK1589","HK0000252160.HKD","LU1634259557.SGD","LU0516423174.USD","HK0000252152.HKD","LU0067412154.USD","LU1951186391.HKD"],"gpt_icon":0},{"id":"2595093322","title":"和鉑醫藥與藍納成宣佈達成長期戰略合作，攜手推進新一代RDC藥物開發","url":"https://stock-news.laohu8.com/highlight/detail?id=2595093322","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595093322?lang=zh_tw&edition=fundamental","pubTime":"2025-12-29 09:58","pubTimestamp":1766973480,"startTime":"0","endTime":"0","summary":"中国上海、美国马萨诸塞州剑桥和荷兰鹿特丹2025年12月29日 /美通社/ -- 和铂医药，一家专注于免疫性疾病和肿瘤领域创新抗体疗法发现及开发的全球生物医药公司，今日宣布与烟台蓝纳成生物技术股份有限公司达成长期战略合作，双方将利用各自资源及优势，共同推进新一代放射性核素偶联药物开发。和铂医药创始人、董事长兼首席执行官王劲松博士表示：\"我们很高兴与蓝纳成建立长期战略合作，共同推进新一代RDC药物开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4854059_ZH54059_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","BK1574","RDC","BK1583","02142"],"gpt_icon":0},{"id":"2593212811","title":"核藥進展如潮湧！遠大醫藥(00512)創新RDC藥物TLX591-CDx國內III期達到主要臨牀終點，診療一體化佈局蓄勢待發","url":"https://stock-news.laohu8.com/highlight/detail?id=2593212811","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593212811?lang=zh_tw&edition=fundamental","pubTime":"2025-12-21 18:14","pubTimestamp":1766312060,"startTime":"0","endTime":"0","summary":"目前，远大医药已有六款创新RDC获批开展注册性临床研究，其中四款已进入III期临床阶段，公司已进入创新核药产品的收获期。尤为值得一提的是，公司自主研发的全球创新FAP靶点小分子RDC药物GPN01530近期获FDA批准在美国开展诊断实体瘤的I/II期临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384114.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","00512","RDC","BK1191","BK4134"],"gpt_icon":0},{"id":"2583574565","title":"市場監管總局局長羅文：市場監管部門將加強反壟斷和反不正當競爭執法","url":"https://stock-news.laohu8.com/highlight/detail?id=2583574565","media":"财闻","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583574565?lang=zh_tw&edition=fundamental","pubTime":"2025-11-13 16:59","pubTimestamp":1763024340,"startTime":"0","endTime":"0","summary":"11月13日，国家市场监督管理总局党组书记、局长罗文接受新华社采访时表示，针对部分地方政府以行政权力干预扭曲市场机制的问题，市场监管部门将围绕破除地方保护和市场分割，加快提高公平竞 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20251113/c672458276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["RDC"],"gpt_icon":0},{"id":"2571792879","title":"羅文在京調研國慶中秋節前食品安全、特種 設備安全及重要民生商品穩價保質等工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2571792879","media":"国家市场监督管...","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571792879?lang=zh_tw&edition=fundamental","pubTime":"2025-09-29 09:37","pubTimestamp":1759109820,"startTime":"0","endTime":"0","summary":"9月28日，市场监管总局党组书记、局长罗文带队在北京调研国庆中秋节前食品安全、特种设备安全及重要民生商品稳价保质等工作。罗文一行前往石景山游乐园、石景山区有关超市和餐饮门店，实地 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20250929/c671495457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["RDC"],"gpt_icon":0},{"id":"2566165802","title":"觀察｜上海浦東：營商服務「最後一公里」，如何成就「最優一公里」？","url":"https://stock-news.laohu8.com/highlight/detail?id=2566165802","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566165802?lang=zh_tw&edition=fundamental","pubTime":"2025-09-09 06:56","pubTimestamp":1757372160,"startTime":"0","endTime":"0","summary":"上海的营商环境改革已从市级的“宏观政策赋能”阶段，进入到街镇的“微观服务决胜”阶段。浦东新区作为营商环境综合示范区，在区营商环境8.0版行动方案中提出，聚焦“打通最后一公里”，着力赋能基层营商环境建设。“优化营商环境，要形成政、企和社区共生的生态，营商环境最后一公里，才可能成为‘最优一公里’。”比如，优化涉企行政检查也是今年上海市营商环境8.0版行动方案的重点任务之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2025-09-09/doc-infpvyaw0691155.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-09-09/doc-infpvyaw0691155.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["RDC"],"gpt_icon":0},{"id":"2565018905","title":"據國藥控股消息近日經上海市藥品監督管理局批准國藥控股所屬分銷中心獲得《放射性藥品經營許可證》國藥控股正式進入放射性核素偶","url":"https://stock-news.laohu8.com/highlight/detail?id=2565018905","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565018905?lang=zh_tw&edition=fundamental","pubTime":"2025-09-08 16:21","pubTimestamp":1757319712,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["NKmain","01099","RDC","BK1515","NIYmain","LU0640798160.USD","NK225MCmain","BK1500","LU0965088593.USD","BK1197","JMImain","JNImain","LU1115378108.SGD"],"gpt_icon":0},{"id":"2563109559","title":"【券商聚焦】中信證券：預計未來中國前列腺癌RDC診療市場將超100億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2563109559","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563109559?lang=zh_tw&edition=fundamental","pubTime":"2025-08-29 08:53","pubTimestamp":1756428810,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券表示，创新核药RDC有望解决目前前列腺癌诊疗过程中检测负担大、疗效有限等未被满足临床需求，改变前列腺癌诊疗范式，实现诊疗一体化，提高患者依从性和生存期。目前中国尚无任何RDC上市，市场呈现蓝海状态，海外前列腺癌RDC诊疗产品在2021年上市，2024年市场已接近30亿美元，充分验证了其巨大的商业价值。该机构认为中国有望复刻海外前列腺癌RDC诊疗市场发展路径，预计未来中国前列腺癌RDC诊疗市场将超100亿元，市场呈现高速增长状态。该机构认为该行业关键点为核素、配体分子形态、生产配送能力，建议关注在上述条件具有优势的公司。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1965099","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1328615791.USD","BK1147","600030","LU2289578879.USD","BK0188","BK0012","LU1064131003.USD","LU1794554557.SGD","LU1997244956.HKD","BK1516","LU2148510915.USD","BK1564","LU1255011170.USD","LU0405327148.USD","BK0183","BK0028","LU1997245177.USD","LU1655091616.SGD","LU0405327494.USD","RDC","BK0196","BK1521","06030","LU1720050803.USD","BK0276","LU2495084118.USD","LU1997245094.SGD","LU1064130708.USD"],"gpt_icon":0},{"id":"2563009585","title":"中信證券研報表示創新核藥RDC有望解決目前前列腺癌診療過程中檢測負擔大、療效有限等未被滿足臨牀需求改變前列腺癌診療範式實","url":"https://stock-news.laohu8.com/highlight/detail?id=2563009585","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563009585?lang=zh_tw&edition=fundamental","pubTime":"2025-08-29 08:43","pubTimestamp":1756428217,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1064131003.USD","600030","LU1997244956.HKD","LU0405327148.USD","LU2289578879.USD","LU2148510915.USD","LU1328615791.USD","BK1516","LU1655091616.SGD","LU0405327494.USD","06030","LU1255011170.USD","LU1794554557.SGD","RDC","BK0196","LU1997245177.USD","BK1147","LU1720050803.USD","BK0188","BK0012","BK1564","BK0028","LU2495084118.USD","BK0183","LU1997245094.SGD","BK1521","BK0276","LU1064130708.USD"],"gpt_icon":0},{"id":"2562082432","title":"思路迪醫藥股份(01244.HK)：新型放射性核素偶聯藥物3D1015首次人體給藥成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2562082432","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562082432?lang=zh_tw&edition=fundamental","pubTime":"2025-08-28 17:36","pubTimestamp":1756373778,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["RDC.AU","BK1161","RDC","01244"],"gpt_icon":0},{"id":"2562035551","title":"思路迪醫藥股份：新型放射性核素偶聯藥物3D1015首次人體給藥成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2562035551","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562035551?lang=zh_tw&edition=fundamental","pubTime":"2025-08-28 17:24","pubTimestamp":1756373083,"startTime":"0","endTime":"0","summary":"格隆汇8月28日丨思路迪医药股份(01244.HK)公告，公司首款自主研发的放射性核素偶联药物(RDC)177Lu-PSMA-3D1015(\"3D1015\")已成功完成首例患者给药。本研究旨在评估3D1015用于PSMA阳性转移性去势抵抗性前列腺癌(mCRPC)患者的安全性与初步疗效。该研究人群精准聚焦于PSMA阳性转移性去势抵抗性前列腺癌(mCRPC)患者。研究将围绕3D1015的核心临床价值展开系统评估，重点包括药物的安全性及辐射剂量学评估，同时将深度收集药物在人体中的药代动力学特征、剂量探索数据，为后续注册临床试验的剂量确定与风险控制提供直接临床依据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508281724549766ec65&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508281724549766ec65&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RDC"],"gpt_icon":0},{"id":"2561257602","title":"中信證券研報表示創新核藥RDC有望解決目前前列腺癌診療過程中檢測負擔大、療效有限等未被滿足臨牀需求改變前列腺癌診療範式實","url":"https://stock-news.laohu8.com/highlight/detail?id=2561257602","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561257602?lang=zh_tw&edition=fundamental","pubTime":"2025-08-24 16:27","pubTimestamp":1756024041,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1997244956.HKD","BK1516","BK1521","LU1655091616.SGD","LU1997245177.USD","BK1564","BK0276","LU1720050803.USD","LU1328615791.USD","LU0405327148.USD","06030","LU1794554557.SGD","600030","BK0188","LU1255011170.USD","LU1064130708.USD","LU1064131003.USD","LU2148510915.USD","LU2289578879.USD","LU1997245094.SGD","LU0405327494.USD","BK0183","BK0196","BK0012","BK0028","BK1147","RDC","LU2495084118.USD"],"gpt_icon":0},{"id":"2561446059","title":"市場監管總局羅文：「十四五」期間審結平台經濟自然壟斷等重點領域的經營者集中案件3400件","url":"https://stock-news.laohu8.com/highlight/detail?id=2561446059","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561446059?lang=zh_tw&edition=fundamental","pubTime":"2025-08-22 10:28","pubTimestamp":1755829706,"startTime":"0","endTime":"0","summary":"8月22日，国家市场监督管理总局局长罗文在国新办发布会上表示，“十四五”期间，加强对重点领域垄断风险的监测评估，强化平台经济常态化监管，为防范和制止网络市场无序竞争设置了红灯划出了底线。持续开展民生领域反垄断执法专项行动。查处医药领域垄断案件，推动药品价格恢复到合理水平。查处供水、燃气、建材、机动车检测等领域垄断案件，有效降低降低公众生活成本和经营主体生产负担。加强对平台经济自然垄断等重点领域的经营者集中审查，共审结案件3400件，查处违法实施经营者集中145件，有力维护公平竞争市场秩序。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/08/22102852605627.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["RDC"],"gpt_icon":0},{"id":"2561455641","title":"從易甘泰到RDC矩陣：核藥龍頭遠大醫藥蓄勢待發","url":"https://stock-news.laohu8.com/highlight/detail?id=2561455641","media":"氨基观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561455641?lang=zh_tw&edition=fundamental","pubTime":"2025-08-21 10:08","pubTimestamp":1755742138,"startTime":"0","endTime":"0","summary":"中国头部创新药企，进入价值释放加速期。近日，备受市场瞩目的核药龙头远大医药公布了中期财报。例如，用于前列腺癌诊断的TLX591-CDx在中国已完成临床三期，预计年内递交新药上市申请。但远大医药已经成为全球打通、建立核药全产业链优势的极少数者。本质上，成都温江的核素研发生产平台投入运营，也是远大医药全球战略加速的信号。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250821124628a6f27fad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250821124628a6f27fad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RDC"],"gpt_icon":0},{"id":"2561045569","title":"中期業績穩健增長 遠大醫藥股價升逾4% 核藥營收翻倍穩居領軍企業地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2561045569","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561045569?lang=zh_tw&edition=fundamental","pubTime":"2025-08-20 18:46","pubTimestamp":1755686770,"startTime":"0","endTime":"0","summary":"资本市场反响强烈，8月20日，公司股价以4.37%的涨幅最终报收9.31港元，或将开启远大医药本年度的新一轮的股价增长周期。上半年，远大医药创新及壁垒产品收入占比约51%，同比提升近15个百分点。在核药领域，远大医药是全球仅有的四家实现创新核药商业化的药企之一。目前，远大医药正在积极推进创新核药“Go Global”。今年上半年，公司成都温江核药研发及生产基地的投运标志着远大医药已实现了从实验室研发到工业化量产的战略性跨越。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250820184845a493d86c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250820184845a493d86c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RDC"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":15,"code":"91000000","status":"200"}]}}